Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
Language English Country Greece Media print
Document type Journal Article
PubMed
30504389
DOI
10.21873/anticanres.13048
PII: 38/12/6771
Knihovny.cz E-resources
- Keywords
- Nivolumab, biomarker, non-small cell lung cancer, overall survival, progression-free survival,
- MeSH
- Survival Analysis MeSH
- Chronic Disease MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Lung Neoplasms complications diagnosis drug therapy mortality MeSH
- Carcinoma, Non-Small-Cell Lung complications diagnosis drug therapy mortality MeSH
- Nivolumab therapeutic use MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Aged MeSH
- Inflammation complications diagnosis mortality MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Nivolumab MeSH
AIM: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. CONCLUSION: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment.
Department of Oncology Charles University 1st Faculty of Medicine Prague Prague Czech Republic
Department of Oncology Palacky University Faculty of Medicine and Dentistry Olomouc Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
References provided by Crossref.org
